Iovance Biotherapeutics Jumps 33% After Raising FY26 Revenue Guidance to $410M-$420M on Amtagvi Demand

Shares of Iovance Biotherapeutics Inc. (IOVA) surged about 33% on Sept. 29, 2026, after the company raised its full-year 2026 total revenue guidance to $410 million to $420 million, citing strong U.S. demand for Amtagvi and Proleukin. The stock was trading at $14.59 on the Nasdaq, up 32.71%, after opening at $12.79 and reaching a session high of $14.60. Over the past year, shares have traded between $1.76 and $14.60. The new guidance midpoint of $415 million represents an increase of $55 million, or roughly 15%, over the prior range of $350 million to $370 million, and implies nearly 60% annual revenue growth.